

2021 Claims and Utilization Review

June 17th, 2022

Presented By | Matt Kramer, Sales Executive
Emily Skaer, Client Consultant

COVID-19 EXPERIENCE

COVID cases and cost

(January 2020 – December 2021)

	# of cases	\$ Cost	\$ Average cost per case
COVID Testing	1,865	\$251,430	–
COVID Positive Cases	257	\$264,978	\$1,031
Plan Commercial Average	–	–	\$4,315

PUBLIC HEALTH

ENGAGEMENT

MDA Health Plan experienced 76% lower cost per COVID case compared to plan. COVID vaccination rates are higher than plan average.

Vaccination rates*

(Source: State of Michigan's MICH database)




*Vaccinated includes fully + partially vaccinated (with intention to complete vaccine schedule).

VIRTUAL + TELEHEALTH CARE

Use of virtual care (January 2020 – December 2021. Month-by-month details are located in the Appendix.)

	# Total Claims	Average Claims (# per month)	Average Members (# per month)	% Change in Members (2020 vs. 2021)
Virtual Visits	377	16	15	-42%
Telehealth – medical	905	38	35	9,111%
Telehealth – mental health	2,216	92	52	95%

Top 5 diagnoses (by number of claims) | Behavioral health diagnoses



USE OF SERVICES


PUBLIC HEALTH

MDA Health Plan members utilized both mental health and medical telehealth services much more in 2021 compared to 2020.

PREVENTION

Preventive exam visit rates | (Per 1,000 members)

MDA Plan



Great job! Continue to promote the value of preventive services.

Preventive exam visits by relationship


	# Visits	# Visits (per 1,000)
Dependent	1,267	903
Employee	1,292	632
Spouse	504	695

ENGAGEMENT

MDA Health Plan members sought preventive exams at a rate 21% higher than plan average. Cancer screening and immunization rates remain higher than plan average.


Cancer screening rates | (% of members)

MDA 2020 MDA 2021 Plan



Immunizations | (% of members)

MDA 2020
MDA 2021
Plan



TOP EPISODES OF CARE

● Better than plan ● In line with plan ● Worse than plan

Episodes	# Members	\$ Cost	% Outlier cost	Prevalence vs. plan	Cost vs. plan	% Change in prevalence (2020 vs. 2021)	% Change in cost (2020 vs. 2021)
Inflammatory bowel disease	42	\$1,039,690	63%	●	●	34%	65%
Obstetrics	135	\$968,638	–	●	●	5%	-26%
Inflammation of skin	791	\$928,419	–	●	●	6%	83%
Diabetes	143	\$738,565	–	●	●	-7%	19%
Cancer of breast	32	\$683,131	53%	●	●	9%	10%
Cardiac electrical conduction disorder	94	\$662,441	42%	●	●	17%	105%
Preventive exam	2,049	\$570,871	–	●	●	6%	5%
Fracture or trauma	265	\$545,241	–	●	●	11%	17%
Knee and lower leg disorders	154	\$501,300	–	●	●	7%	5%
Neck and back disorders	547	\$487,908	–	●	●	5%	0%
Cancer of the bone	4	\$483,104	78%	●	●	-1%	1,432%
Exposure to infectious diseases	1,630	\$463,468	–	●	●	12%	7%
Non-cancerous tumor/lesion of female reproductive system	119	\$372,759	–	●	●	12%	21%
Depression	422	\$347,679	–	●	●	-8%	7%
Multiple sclerosis	12	\$340,488	19%	●	●	49%	24%

Yellow represents MDA Health Plan's performance of +/- 10% points around the plan average and is a confidence interval that is useful for interpretation given the size of the group.


TOP 10 DRUG COST (BY CONDITION)

Condition	# Members	# Scripts	\$ Total cost	\$ Cost / script	\$ PMPM	% Change PMPM	Priority Health Plan
Dermatology*	689	1,370	\$1,042,296	\$761	\$21.06	115%	Dermatology*
Inflammatory conditions*	404	987	\$830,483	\$841	\$16.78	34%	Inflammatory conditions*
Diabetes	140	1,673	\$527,052	\$315	\$10.65	20%	Diabetes
Neurological conditions*	17	91	\$316,137	\$3,474	\$6.39	17%	Neurological conditions*
Respiratory agents*	1	11	\$253,923	\$23,084	\$5.13	-8%	Respiratory agents*
Asthma and COPD	361	1,848	\$199,691	\$108	\$4.04	8%	Asthma and COPD
ADHD and sleep disorders	217	1,751	\$195,860	\$112	\$3.96	-5%	ADHD and sleep disorders
Cancer and transplant*	42	227	\$184,876	\$814	\$3.74	-21%	Cancer and transplant*
Endocrinology*	30	235	\$180,624	\$769	\$3.65	328%	Endocrinology*
Anticoagulants	44	346	\$154,155	\$446	\$3.11	15%	Anticoagulants
Total					\$78.51	50% (average)	



*Influenced by specialty medications

RX SNAPSHOT


Number of prescriptions PMPY




Number of prescriptions PMPY



Tier 1 drug use




SPECIALTY DRUGS




Specialty spend PMPM

(with % of total drug spend)



Average specialty drug use and allowed amount



Conditions with specialty spend > \$50,000

- Dermatology
- Inflammatory conditions
- Cystic fibrosis
- Hematological conditions
- Endocrinology

PHARMACY STRATEGIES TO LOWER TREND

Medical injectable management

- Biosimilar
- Site of service

Top conditions treated	\$ Total cost
Oncology	\$651,574
Inflammatory	\$152,005
Immunology	\$121,674
Pulmonology	\$103,893
Neurology	\$30,479
Psychiatry	\$24,243
Chemical dependency	\$15,077
Ophthalmology	\$13,349
Rabies	\$7,847
Hepatology	\$7,219
Total	\$1,127,361

PMPM	MDA Health Plan	Plan
2021	\$40.02	\$39.76
2020	\$31.94	\$35.83
2019	\$31.25	\$35.63

Formulary management

P&T committee comprised of statewide primary care physicians, specialists and practicing pharmacist evaluates all new and existing drugs. Their decisions involve annual drug class reviews and appropriate tiering.

They also consider:

- Step therapy
- Prior authorization
- Quantity limits / day limits
- Exclusion of high-cost drugs with limited clinical value

For 2021, **64% of the total 268 prior authorization (PA) requests** for MDA Health Plan members were redirected to a lower cost alternative, a preferred formulary drug, or were otherwise not approved (*e.g., excluded drugs, requests to exceed FDA dosing limits*).

CARE MANAGEMENT & MEDICATION THERAPY MANAGEMENT

Medical member engagement

by intervention type

Care coordination: Helping members with complex medical needs navigate complex medical needs to ensure they receive high quality care.

Care transitions: Brief, intensive engagement when a member transitions from the acute or sub-acute setting to home to prevent readmission.

Complex care management

Proactive outreach to members with chronic conditions and at risk of worsening health.

	Targeted	Engaged	
	#	#	%
Medical			
Complex care management	12	2	17%
Care transitions	24	16	67%
Care coordination	0	0	0%
Total	36	18	50%

Medication Therapy Management (MTM)

MTM helps members taking medications for chronic conditions understand their drugs and maximize their results while controlling their out-of-pocket costs. Qualified members receive a face-to-face consultation with a pharmacist.

Of all attempts			
	% CMR completed	% Unable to reach	% Refused
MDA Health Plan	64%	13%	22%
Priority Health plan	74%	11%	16%
	Targeted Members	% Completed	
MDA Health Plan	176	33%	
Priority Health plan	—	43%	

Top benefits of MTM:

- Better compliance
- Lower cost alternatives
- Reduce drug to drug interaction/hospital visits

RESOLUTION TO ADD INCENTIVE FOR CASE MANAGEMENT & MEDICATION THERAPY MANAGEMENT

Resolved that, the MDA Health Plan board approves a one-time \$75 incentive to be paid to the member, who work with either Priority Health or their pharmacist for medication therapy management or care management and engage in the program, and let it further be resolved that Priority Health would need to be able to monitor, track and pay out the incentive all on their end.